DOT1L cooperates with the c-Myc–p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
DOT1L has emerged as an anticancer target for MLL-associated leukaemias; however, its functional role in solid tumours is largely unknown. Here we identify that DOT1L cooperates with c-Myc and p300 acetyltransferase to epigenetically activate epithelial–mesenchymal transition (EMT) regulators in breast cancer progression. DOT1L recognizes SNAIL, ZEB1 and ZEB2 promoters via interacting with the c-Myc-p300 complex and facilitates lysine-79 methylation and acetylation towards histone H3, leading to the dissociation of HDAC1 and DNMT1 in the regions. The upregulation of these EMT regulators by the DOT1L-c-Myc-p300 complex enhances EMT-induced breast cancer stem cell (CSC)-like properties. Furthermore, in vivo orthotopic xenograft models show that DOT1L is required for malignant transformation of breast epithelial cells and breast tumour initiation and metastasis. Clinically, DOT1L expression is associated with poorer survival and aggressiveness of breast cancers. Collectively, we suggest that cooperative effect of DOT1L and c-Myc-p300 is critical for acquisition of aggressive phenotype of breast cancer by promoting EMT/CSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“DOT1L drives the expression of genes associated with epithelial-mesenchymal transition (EMT) in breast cancer [79] and is also a key regulator of hematopoiesis [80], making it a therapeutic target in MLL-rearranged leukemias [81].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
Cancer stem cells: mirage or reality?
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 979
Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State
Guo, W., Keckesova, Z., Donaher, J. L., Shibue, T., Tischler, V., Reinhardt, F., Itzkovitz, S., Noske, A., Zürrer-Härdi, U., Bell, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.008 · Cited by 957
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
Scheel, C., & Weinberg, R. A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.04.001 · Cited by 881
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
hDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Cited by
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
The language of chromatin modification in human cancers
Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00357-x · Cited by 402
Branched-chain amino acid metabolism in cancer
Ananieva, E. A., & Wilkinson, A. C. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000430 · Cited by 291
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity
Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N., & Berx, G. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.004 · Cited by 271
Emerging role of PI3K/AKT in tumor-related epigenetic regulation
Yang, Q., Jiang, W., & Hou, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.04.001 · Cited by 202
DOT1L and H3K79 Methylation in Transcription and Genomic Stability
Wood, K., Tellier, M., & Murphy, S. (2018) · Biomolecules · doi:10.3390/biom8010011 · Cited by 209
“C-Myc is essential for the presence of DOT1L and H3K79me2 at several genomic loci, suggesting that c-Myc targets the enzyme to these loci [54].”
BackgroundLysine acetylation and cancer: A proteomics perspective
Gil, J., Ramírez-Torres, A., & Encarnación-Guevara, S. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2016.10.003 · Cited by 184
ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis
Chen, Y., Zhang, B., Bao, L., Jin, L., Yang, M., Peng, Y., Kumar, A., Wang, J. E., Wang, C., Zou, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95089 · Cited by 174
Deng, J., Li, Y., Yin, L., Liu, S., Li, Y., Liao, W., Mu, L., Luo, X., & Qin, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07498-z · Cited by 169
Epigenetic regulation of epithelial–mesenchymal transition
Sun, L., & Fang, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2303-1 · Cited by 159
“This H3K79 HMTase forms a complex with c-Myc and p300 on the promoter of SNAI1 and ZEB1/2, while the catalyzed H3K79 methylation coordinates with other epigenetic marks to activate their expression to promote EMT and metastasis [105].”
Luo, L., Tang, H., Li, L., Li, N., Jia, X., Zhang, Z., Wang, X., Shi, L., Yin, J., Qiu, N., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0396-8 · Cited by 151
Self-citationLee, J.-Y., Park, J.-H., Choi, H.-J., Won, H.-Y., Joo, H., Shin, D.-H., Park, M. K., Han, B., Kim, K. P., Lee, T. J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.158 · Cited by 147
Self-citationLee, J., & Kong, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2313-z · Cited by 137
“Consistent with this observation, recent studies reported by our group have suggested that c-Myc, a basic helix-loop helix (bHLH) transcription factor that specifically recognizes the E-box motif, is a common transcription factor for the induction of Snail, ZEB1, and ZEB2 expression [20] [21].”
BackgroundInfluentialSelf-citationCancer epigenetics: Past, present and future
Lee, J. E., & Kim, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.025 · Cited by 148
Self-citationChoi, H., Jin, S., Cho, H., Won, H., An, H. W., Jeong, G., Park, Y., Kim, H., Park, M. K., Son, T., et al. (2019) · EMBO reports · doi:10.15252/embr.201948058 · Cited by 117
“Cells were lysed with radioimmunoprecipitation buffer containing protease-inhibitor and phosphatase-inhibitor cocktails, and immunoblot was performed as previously described [50].”
InfluentialSelf-citationMYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis
Meškytė, E. M., Keskas, S., & Ciribilli, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207710 · Cited by 116
The upstreams and downstreams of H3K79 methylation by DOT1L
Vlaming, H., & van Leeuwen, F. (2016) · Chromosoma · doi:10.1007/s00412-015-0570-5 · Cited by 114
“* Fred van Leeuwen fred.v.leeuwen@nki.nl (Bernt and Armstrong 2011; Kim et al. 2012b; Zhang et al. 2014; Cho et al. 2015).”
BackgroundEMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells
Lindner, P., Paul, S., Eckstein, M., Hampel, C., Muenzner, J. K., Erlenbach‐Wuensch, K., Pallikonda, H. A., Mahadevan, V., Brabletz, T., Hartmann, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2340-4 · Cited by 106
Zhang, X., Liu, D., Li, M., Cao, C., Wan, D., Xi, B., Li, W., Tan, J., Wang, J., Wu, Z., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0400-8 · Cited by 101
“ChIP assays were performed following the protocols as previously described [13, 29, 30].”
MethodA Linc1405/Eomes Complex Promotes Cardiac Mesoderm Specification and Cardiogenesis
Guo, X., Xu, Y., Wang, Z., Wu, Y., Chen, J., Wang, G., Lu, C., Jia, W., Xi, J., Zhu, S., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.04.013 · Cited by 107
“DOT1L and p300 are recruited to the promoters of the CDH1 gene to regulate breast cancer progression (Cho et al., 2015).”
Nassa, G., Salvati, A., Tarallo, R., Gigantino, V., Alexandrova, E., Memoli, D., Sellitto, A., Rizzo, F., Malanga, D., Mirante, T., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav5590 · Cited by 91
Yuan, S., Natesan, R., Rivera, F. J. S., Li, J., Bhanu, N. V., Yamazoe, T., Lin, J., Merrell, A. J., Sela, Y., Thomas, S. K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1299 · Cited by 98
“For example, other potential targets from our screen, such as KDM1A, which has been shown to interact with SNAI1 to drive EMT (13), and DOT1L, which was recently demonstrated to regulate EMT in breast cancer (61), already have inhibitors that are currently being tested in clinical trials for various cancers.”
BackgroundSharma, M., & Tollefsbol, T. O. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113160 · Cited by 91
Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics
Kaypee, S., Sudarshan, D., Shanmugam, M. K., Mukherjee, D., Sethi, G., & Kundu, T. K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.011 · Cited by 97
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Koh, C. M., Sabò, A., & Guccione, E. (2016) · BioEssays · doi:10.1002/bies.201500134 · Cited by 102
“This supports the possibility that in other contexts, such as during the initiation of cancer metastasis, the regulation of various splicing factors by MYC may contribute to EMT/MET.”
BackgroundJeong, G., Park, M. K., Choi, H., An, H. W., Park, Y.-U., Choi, H.-J., Park, J. H., Kim, H.-Y., Son, T., Lee, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0360 · Cited by 88
Self-citationRoles of Grainyhead-like transcription factors in cancer
Frisch, S. M., Farris, J. C., & Pifer, P. M. (2017) · Oncogene · doi:10.1038/onc.2017.178 · Cited by 87
Zeng, Q.-M., Wang, K., Zhao, Y., Ma, Q., Chen, Z., & Huang, W. (2023) · Biomolecules · doi:10.3390/biom13030417 · Cited by 86
“It has also been demonstrated that DOT1L interacts with the p300/c-Myc complex to enhance EMT-induced stemness properties by recognising promoters such as those of ZEB1 and ZEB2; this promotes DNA methylation and histone acetylation, enhances epithelial−mesenchymal transition (EMT) regulators, and accelerates the mali…”
BackgroundLiang, Y., Wu, Y., Chen, X., Zhang, S., Wang, K., Guan, X., Yang, K., Li, J., & Bai, Y. (2017) · Bioscience Reports · doi:10.1042/bsr20171019 · Cited by 84
The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription
Wong, M., Tee, A. E., Milazzo, G., Bell, J. L., Poulos, R. C., Atmadibrata, B., Sun, Y., Jing, D., Ho, N., Ling, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1663 · Cited by 87
Improved survival analysis by learning shared genomic information from pan-cancer data
Kim, S., Kim, K., Choe, J., Lee, I., & Kang, J. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa462 · Cited by 77
MYC dysfunction modulates stemness and tumorigenesis in breast cancer
Liu, Y., Zhu, C., Tang, L., Chen, Q., Guan, N., Xu, K., & Guan, X. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.51458 · Cited by 81
“MYC increases breast cancer stem cell-like properties and EMT by binding to DOT1L and p300, which stimulates SNAIL, ZEB1, ZEB2 transcription and promotes lysine-79 methylation and H3 acetylation through gene epigenetic modification [58].”
BackgroundDOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Kurani, H., Razavipour, S. F., Harikumar, K. B., Dunworth, M., Ewald, A. J., Nasir, A., Pearson, G. W., Booven, D. V., Zhou, Z., Azzam, D. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1299 · Cited by 79
“Notably, DOT1L was also shown to regulate TISC abundance in both ERþ and ER breast cancer models (41).”
BackgroundInfluentialDarvin, P., Nair, V. S., & Elkord, E. (2019) · Journal of Oncology · doi:10.1155/2019/3958908 · Cited by 77
“HAT (p300/CBP) is a transcriptional coactivator of histone acetyltransferase enzyme family that are responsible for epigenetic activation of EMT transcription factors, promoting breast cancer aggressiveness [25].”
BackgroundThe Histone Deacetylase SIRT6 Restrains Transcription Elongation via Promoter-Proximal Pausing
Etchegaray, J., Zhong, L., Li, C., Henriques, T., Ablondi, E. F., Nakadai, T., Rechem, C. V., Ferrer, C. M., Ross, K. N., Choi, J.-E., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.06.034 · Cited by 79
“, 2015), while MYC interacts with DOT1L, the only known histone methyltransferase to catalyze methylation of H3K79, to induce transcription activation (Cho et al., 2015; Wong et al., 2017).”
Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies
Thakur, C., Qiu, Y., Fu, Y. S., Bi, Z., Zhang, W., Ji, H., & Chen, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971288 · Cited by 81
Ring, A., Kaur, P., & Lang, J. E. (2020) · BMC Cancer · doi:10.1186/s12885-020-07573-y · Cited by 77
“EP300 has been implicated in cancer biology in general [15] and breast cancer in particular [16], and has been described as both a tumor suppressor [16, 17] and more recently as an oncogene promoting tumor growth, metastatic potential and CSC phenotype in BC [18]–[20].”
BackgroundTargeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Yi, Y., & Ge, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01251-1 · Cited by 75
“On the other hand, DOT1L, as one main component, may be involved in c-Mycdependent transcriptional and epigenetic regulation [92, 93].”
BackgroundRole of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer
Choi, H., Joo, H.-S., Won, H., Min, K., Kim, H.-Y., Son, T., Oh, Y., Lee, J., & Kong, G. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx207 · Cited by 72
Self-citationDOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A
Leon, K. E., Buj, R., Lesko, E., Dahl, E. S., Chen, C.-W., Tangudu, N. K., Imamura-Kawasawa, Y., Kossenkov, A. V., Hobbs, R. P., & Aird, K. M. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202008101 · Cited by 70
“Additionally, DOT1L has multiple binding partners or inhibitors that could affect its recruitment to particular loci, including C/EBP β itself (Altaf et al., 2007; Cho et al., 2015; Fingerman et al., 2007; Liu et al., 2018; Wakeman et al., 2012; Wood et al., 2018).”
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 82
Michalak, E. M., & Visvader, J. E. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.003 · Cited by 74
Zhuang, J., Huo, Q., Yang, F., & Xie, N. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.603552 · Cited by 74
Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment
Yang, Y., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640369 · Cited by 74
Epigenetic regulation of cancer stemness
Galassi, C., Manic, G., Esteller, M., Galluzzi, L., & Vitale, I. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02340-6 · Cited by 69
“61 127 At least in the latter setting, this also involves H3 acetylation by EP300 as well as MYC activation.”
InfluentialCBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis
Liu, C., Yang, Q., Zhu, Q., Lu, X., Li, M., Hou, T., Li, Z., Tang, M., Li, Y., Wang, H., et al. (2020) · Theranostics · doi:10.7150/thno.39013 · Cited by 62
“When DOT1L is highly expressed, H3K79 methylation levels around the SNAIL and ZEB1 promoters are high; this effect leads to SNAIL and ZEB1 expression and repressed CDH1 (encoding E-cadherin) transcription [21].”
BackgroundMethodInfluentialThe role of DOT1L in the maintenance of leukemia gene expression
Wang, X., Chen, C.-W. D., & Armstrong, S. A. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.015 · Cited by 64
Epigenetic determinants of metastasis
Patel, S. A., & Vanharanta, S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.008 · Cited by 67
“The H3K79 methyltransferase DOT1L promotes breast cancer metastasis by activating many EMT mediators in collaboration with c-MYC (Cho et al., 2015).”
BackgroundLi, Z., Yang, Z., Liu, W., Zhu, W., Yin, L., Han, Z., Xian, Y., Wen, J., Tang, H., Lin, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04120-8 · Cited by 62
“It is well known that c-Myc is one of direct target genes in Wnt/β-catenin signaling downstream, and involved in both EMT and CSLCs traits in the progression of cancers including breast and liver cancer [65, 66].”
BackgroundYang, L., Lei, Q., Li, L., Yang, J., Dong, Z., & Cui, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0778-y · Cited by 59
Hu, Y., Zheng, Y., Dai, M., Wang, X., Wu, J., Yu, B., Zhang, H., Cui, Y., Kong, W., Wu, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14173 · Cited by 58
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong, M., Polly, P., & Liu, T. (2015) · Europe PMC (PubMed Central) · Cited by 76
Li, Y., & Cheng, C. (2018) · PubMed · Cited by 57
RetractedOktyabri, D., Ishimura, A., Tange, S., Terashima, M., & Suzuki, T. (2016) · Biochimie · doi:10.1016/j.biochi.2016.01.005 · Cited by 56
Evanno, E., Godet, J., Piccirilli, N., Guilhot, J., Milin, S., Gombert, J. M., Fouchaq, B., & Roche, J. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0380-0 · Cited by 56
Chen, X. '., Liu, X., Zhang, Y., Huai, W., Zhou, Q., Xu, S., Chen, X., Li, N., & Cao, X. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0170-4 · Cited by 55
Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors
Alexandrova, E., Salvati, A., Pecoraro, G., Lamberti, J., Melone, V., Sellitto, A., Rizzo, F. M., Giurato, G., Tarallo, R., Nassa, G., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.864612 · Cited by 56
Ervin, E.-H., French, R., Chang, C., & Pauklin, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.001 · Cited by 56
Wang, S., Sheng, H., Zheng, F., & Zhang, F. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153499 · Cited by 53
Epigenetic Targets and their Inhibitors in Cancer Therapy
Zhao, L., Duan, Y., Lü, P., Zhang, Z., Zheng, X., Wang, J., & Feng, W. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181224095449 · Cited by 54
The role of branched chain amino acids metabolic disorders in tumorigenesis and progression
Wang, J., Wang, W., Zhu, F., & Duan, Q. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113390 · Cited by 51
Epigenetic regulation of hybrid epithelial-mesenchymal cell states in cancer
Sample, R. A., Nogueira, M. F., Mitra, R. D., & Puram, S. V. (2023) · Oncogene · doi:10.1038/s41388-023-02749-9 · Cited by 51
Tikhanovich, I., Zhao, J., Bridges, B., Kumer, S. C., Roberts, B., & Weinman, S. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.797928 · Cited by 51
“Transac va on domain MYC N (1-345) HLH(355-407) LZ(408-438)”
BackgroundProminent Role of Histone Modifications in the Regulation of Tumor Metastasis
Markouli, M., Strepkos, D., Basdra, E. K., Papavassiliou, A. G., & Piperi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052778 · Cited by 52
“EMT regulators in breast cancer, and serving as a potential oncogene responsible for the formation of an aggressive phenotype and transformation of cancer stem cells (CSCs) [87].”
BackgroundPhenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis
Paiva, B., Martínez‐López, J., Corchete, L. A., Sánchez-Vega, B., Rapado, I., Puig, N., Barrio, S., Sánchez, M.-L., Alignani, D., Lasa, M., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673095 · Cited by 50
Pifer, P. M., Farris, J. C., Thomas, A. L., Stoilov, P., Denvir, J., Smith, D. M., & Frisch, S. M. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-04-0249 · Cited by 52
“With regard to cancer, transcription factors that use p300/CBP and additional coactivators that interact with p300/CBP have been implicated in the oncogenic EMT, tumor drug resistance, and tumor recurrence (Matthews et al., 2007; Qin et al., 2009; Santer et al., 2011; Zhou et al., 2012; Delvecchio et al., 2013; Ringel…”
BackgroundEpigenetic Regulation and Post-Translational Modifications of SNAI1 in Cancer Metastasis
Dong, B., & Wu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011062 · Cited by 51
“In breast cancers, DOT1L forms a transcriptionally active complex with c-Myc and p300 to facilitate H3K79 methylation and acetylation in the promoter regions of SNAI1 that enhances SNAI1 de-repression, consequently promoting EMT [86].”
BackgroundHe, B., Gao, R., Lv, S., Chen, A., Huang, J., Wang, L., Feng, Y., Feng, J., Liu, B., Lei, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01487-4 · Cited by 47
“4,27,28 Indeed, sphere-forming capacity predicts in vivo CSC frequencies in 30 cell lines, con fi rming the enrichment of functional stemness in oncospheres (Supplementary Fig.”
Park, J., Kim, Y. H., Shim, S., Kim, A., Jang, H., Lee, S., Park, S., Seo, S., Jang, W. I., Lee, S. B., et al. (2021) · Cells · doi:10.3390/cells10010135 · Cited by 47
“Invasion assay was performed as previously reported [18].”
MethodSelf-citationTargeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way
Li, W., Wu, H., Sui, S., Wang, Q., Xu, S., & Pang, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.736935 · Cited by 49
DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC
Wang, Y., Ju, L., Wang, G., Qian, K., Jin, W., Li, M., Yu, J., Shi, Y., Wang, Y., Zhang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38160-x · Cited by 43
The role of H3K79 methylation in transcription and the DNA damage response
Ljungman, M. E., Parks, L., Hulbatte, R. S., & Bedi, K. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.11.001 · Cited by 46
Feng, J., & Meng, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.946811 · Cited by 43
“H3 acetylation in the promoters of Snail, ZEB1, and ZEB2 promotes the CSC-like characteristics within BC cells (Cho et al., 2015).”
BackgroundByun, W. S., Kim, W. K., Han, H., Chung, H., Jang, K., Kim, H. S., Kim, S., Kim, D., Bae, E. S., Park, S., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.09.005 · Cited by 43
“It is known that the selective inhibition of H3K79 di-methylation suppresses the proliferation and progression of breast cancer.(8) Therefore, a cell proliferation assay against”
BackgroundInfluentialSelf-citationA three layered histone epigenetics in breast cancer metastasis
Nandy, D., Rajam, S. M., & Dutta, D. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00415-1 · Cited by 43
Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer
Dong, B., Qiu, Z., & Wu, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.596239 · Cited by 42
Cao, L., Zhang, Y., Dong, S., Li, X., Tong, X., Chen, D., Wu, Z., Zheng, X., Xue, W., Jia, W., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01905-x · Cited by 42
“For example, BRD4 promoted gastric cancer metastasis through stabilization of Snail [6] and another BRD protein EP300 cooperated with cMyc and DOT1L to derepress CDH1 transcription factors thus helping acquisition of aggressive phenotype of breast cancer [11].”
BackgroundLiu, L., Zou, J., Guan, Y. A., Zhang, Y., Zhang, W., Zhou, X., Xiong, C., Tolbert, E. M., Zhao, T. C., Bayliss, G. P., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201801861r · Cited by 43
“Activation of those transcription factors is able to repress the transcription of encoding E-cadherin (CDH1), a hallmark of renal epithelial cells, and plays a crucial role in the acquisition of dedifferentiated cell types (42).”
BackgroundWang, Y., Xie, Q., Tan, H., Liao, M., Zhu, S., Zheng, L., Huang, H., & Liu, B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105702 · Cited by 44
Role of c-Myc in lung cancer: Progress, challenges, and prospects
Wallbillich, N. J., & Lu, H. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.07.001 · Cited by 39
“48 Recently, GATA zinc finger domain containing 2B (GATAD2B), a member of the nucleosome remodeling complex, was shown to directly interact with c-Myc in a KRAS-driven lung cancer to promote EMT-driven metastasis.”
Nan, Y., Luo, Q., Wu, X., Chang, W., Zhao, P., Liu, S., & Liu, Z. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.006 · Cited by 39
Histone lysine methylation and congenital heart disease: From bench to bedside (Review)
Yi, X., Jiang, X., Li, X., & Jiang, D. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3115 · Cited by 38
“In recent years, studies have shown that histone lysine methylation is not only closely related to tumor occurrence and development, developmental defects, senile dementia, cardiac hypertrophy and other clinical diseases, but also participates in the occurrence of CHD, influencing the development of heart structure an…”
Salvati, A., Gigantino, V., Nassa, G., Giurato, G., Alexandrova, E., Rizzo, F. M., Tarallo, R., & Weisz, A. (2019) · Cancers · doi:10.3390/cancers11111720 · Cited by 38
Jiang, Q., Zhou, Y. C., Yang, H., Li, L., Deng, X., Cheng, C., Xie, Y., Luo, X., Fang, W., & Liu, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11691 · Cited by 37
Fructose-1,6-bisphosphatase is a novel regulator of Wnt/β-Catenin pathway in breast cancer
Li, K., Ying, M., Feng, D., Du, J., Chen, S., Dan, B., Wang, C., & Wang, Y. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.050 · Cited by 37
Xie, W., Zhang, Y., Wang, B., Hu, Y., Zhan, B., Wei, F., Tang, J., & Lian, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3310 · Cited by 37
Epithelial mesenchymal transition and resistance in endocrine-related cancers
Čulig, Z. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.05.003 · Cited by 35
Liu, Q.-L., Luo, M., Huang, C., Chen, H., & Zhou, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657546 · Cited by 37
“addition, other chromatin modifiers, including DNA methyltransferases (DNMTs) (25), histone methyltransferases (HTMs) (26), histone acetyltransferases (HATs) and histone deacetylases (HDACs) (27, 28), chromatin-remodeling complexes such as PRC1 (29) and SWI/SNF (30), have been implicated in the interplay with EMT-TFs,…”
BackgroundRegulation of epithelial-mesenchymal transition by protein lysine acetylation
Kong, F., Ma, L., Wang, X., You, H., Zheng, K., & Tang, R. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00870-y · Cited by 35
“Snail1 EMT-TF Up DOT1L P300 H3 Breast cancer cells [46]”
BackgroundInfluentialAdvances on Innate Immune Evasion by Avian Immunosuppressive Viruses
Wang, H., Li, W., & Zheng, S. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901913 · Cited by 40
Epigenetic regulation of breast cancer metastasis
Thakur, C., Qiu, Y., Pawar, A. S., & Chen, F. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10146-7 · Cited by 37
“One of the major transcriptional coactivators and HATs is the P300 that regulates EMT and acts as an oncogene for the attainment of aggressive traits of breast cancer [257].”
Duan, X., Fu, Z., Gao, L., Zhou, J., Deng, X., Luo, X., Fang, W., & Luo, R. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw099 · Cited by 35
Yao, L., Jiang, L., Zhang, F., Li, M., Yang, B., Zhang, F., & Guo, X. (2020) · Bioscience Reports · doi:10.1042/bsr20200382 · Cited by 32
Song, Q., Yao, L., Shao, L., Li, W., Kong, Q., Lin, Z., Qin, X., Wei, W., Hou, F., Li, J., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab016 · Cited by 34
Bai, L., Ma, Y., Wang, X., Feng, Q., Zhang, Z., Wang, S., Zhang, H., Lu, X., Xu, Y., Zhao, E., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.587218 · Cited by 34
“All the primary antibodies used in this study are listed here: p21 (1:1,000, Cell Signaling Technology, United States), p27 (1:1,000, Cell Signaling Technology, United States), CDK2 (1:1,000, Cell Signaling Technology, United States), CDK4 (1:1,000, Cell Signaling Technology, United States), Cyclin D1 (1:1,000, Cell S…”
BackgroundInfluentialDiscovery of Bisubstrate Inhibitors for Protein N-Terminal Methyltransferase 1
Chen, D., Dong, G., Noinaj, N., & Huang, R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00206 · Cited by 34
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics
Janin, M., Dávalos, V., & Esteller, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10120-3 · Cited by 35
“The resulting epigenetic activation of EMT transcription factors promotes EMT-induced cancer stem cell properties and enhances the invasive and metastatic abilities in breast cancer, possibly reversed by the use of DOT1L inhibitor [137].”
BackgroundPARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
Liu, C., Li, J., Xu, F., Chen, L., Ni, M., Wu, J., Zhao, H., Wu, Y., Li, J., Wu, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02025-8 · Cited by 31
“In fact, previous literature showed that DOT1L appears to influence cancer cell migration, invasion, and metastasis more prominently [28, 44, 45], agreeing with our results depicted in Fig.”
BackgroundResultKara, N., Kent, M. R., Didiano, D., Rajaram, K., Zhao, A. H., Summerbell, E. R., & Patton, J. G. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.061 · Cited by 31
“Dot1l has also been reported to associate with the c-Myc-p300 complex to activate epithelial-mesenchymal transition regulators (Cho et al., 2015).”
Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response
Lee, R. S., Sad, K., Fawwal, D. V., & Spangle, J. M. (2023) · Cancers · doi:10.3390/cancers15154005 · Cited by 33
“This is concurrent with H3 acetylation enrichment at the SNAI1, ZEB1, and ZEB2 promoters, alongside an increase in H3K79 methylation [74].”
BackgroundInfluential
Metadata
- Authors
- Cho, M.-H., Park, J.-H., Choi, H.-J., Park, M.-K., Won, H.-Y., Park, Y.-J., Lee, C. H., Oh, S.-H., Song, Y.-S., Kim, H. S., Oh, Y.-H., Lee, J.-Y., & Kong, G.
- Affiliations
- Hanyang University (KR)
- Dongguk University (KR)
- Gachon University (KR)
- Corresponding author
- Lee, Jeong-Yeon
- Kong, Gu
- ORCID
- Venue
- Nature Communications
- Published
- 2015-07-22
- Volume
- 6
- Issue
- 1
- Pages
- 7821-7821
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4525167
- OpenAlex
- W1620051969
- Cited by
- 211
- References
- 39
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 19 · 2023: 21 · 2022: 29 · 2021: 24 · 2020: 22 · 2019: 20 · 2018: 10 · 2017: 18 · 2016: 23 · 2015: 3
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Royal Society of Chemistry’s Journals, Books and Databases (The Royal Society of Chemistry) (submittedVersion)
- The Royal Society of Chemistry’s Journals, Books and Databases (The Royal Society of Chemistry) (submittedVersion, cc-by)
- Funders
- National Research Foundation
- National Research Foundation of Korea
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- DOT1L, c-Myc, P300, epithelial-mesenchymal transition, breast cancer progression, histone H3 lysine 79 methylation, histone acetylation, snails, ZEB1, ZEB2, HDAC1, DNMT1, breast cancer stem cells, metastasis, tumor initiation
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Methyltransferases, Neoplasm Metastasis, Histone-Lysine N-Methyltransferase, Neoplastic Stem Cells, Case-Control Studies, Proto-Oncogene Proteins c-myc, Mice, SCID, Mice, Inbred NOD, Disease Progression, Epigenesis, Genetic, Cell Line, Tumor, E1A-Associated p300 Protein, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.